Dr. Reddy's Laboratories Ltd.
DRREDDY · NSE · Healthcare
₹1,279.5
+4.10 (+0.32%)
Our verdict
Hold45/100
Quality47
Valuation68
Momentum52
Financial trend0
Intrinsic value
Our fair value
₹1,277.47
Fairly valued
Price ₹1,279.5Range ₹43.49–₹2,511.45
With a 20% margin of safety, our buy-below price is ₹1,021.98.
A
Financial health 98/100
Altman Z 4.92 · Safe zone
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
Passed 6 of 13 checks46/100
- ✕ROE above 15%11.8%
- ✓Low debt (D/E < 0.5)0.20x
- ✓Positive free cash flow
- ✕Revenue growth > 10%-12%
- ✕Earnings growing-86%
- ✓Net margin ≥ 10%12.8%
- ✓Current ratio > 1.51.80
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 4.92
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-151W
+0.3%
1M
-4.3%
3M
-3.0%
6M
+2.3%
1Y
—
Our scores
Durability47
Valuation86
Momentum52
Analyst consensus target ₹1,331.77 (+4%) · 39 analysts
Key fundamentals
Market cap
₹1.07 L Cr
P/E ratio
24.9
P/B ratio
2.83
EPS (TTM)
₹51.4
ROE
11.8%
Debt / Equity
0.20x
Profit margin
12.8%
Free cash flow
₹163 Cr
52-week high
₹1,354.6
-5.54% from high
52-week low
₹1,157.2
Dividend yield
0.6%
Beta
0.26
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 4.92.
Weaknesses
- •Weak Piotroski score (3/9).
Opportunities
- •Trading in our value buy zone versus sector peers.
Threats
- •Earnings contracting year on year.
About Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.